Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for isosorbide mononitrate
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on isosorbide mononitrate or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on isosorbide mononitrate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
[Isosorbide-5-mononitrate in the prevention of digestive hemorrhage in cirrhosis: randomized study]. Isosorbide 5-mononitrate (5MI) is a preferential venous dilator that has been shown to decrease portal pressure in acute and long-term haemodynamic studies, and this is not associated with adverse effects on hepatic perfusion. The aim of this trial was to investigate the efficacy and safety of 5MI in the prevention of upper gastrointestinal bleeding in cirrhotic patients. Forty two cirrhotic
[Selection of therapy with nitrates in patients with stable effort angina: results of comparative study of common isosorbide dinitrate and long acting preparation of isosorbide-5-mononitrate]. To assess efficacy and tolerability of a novel drug form of isosorbide-5-mononitrate in patients with ischemic heart disease and stable effort angina as compared with common isosorbide dinitrate pills.Patients with stable class II-III effort angina (n=30) were included into a randomized crossover study (...) in which they received isosorbide dinitrate (nitrosorbide, 10-20 mg t.i.d.) and long acting isosorbide-5-mononitrate (ephox-long, 50-100 mg o.d.) for 3 weeks each. Efficacy of treatment was assessed by clinical data and treadmill exercise tests. Questionnaires were used for registration of frequency and intensity of attacks of headache.The use of both isosorbide dinitrate and 5-mononitrate was associated with significant improvements of exercise tolerance however effect of mononitrate lasted longer
Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Meta-analysis: isosorbide-mononitrate alone or with either beta-blockers or endoscopic therapy for the management of oesophageal varices Gluud LL, Langholz E, Krag A CRD summary This review reported that isosorbide (...) mononitrate alone or in combination with beta blockers did not appear to reduce bleeding in primary or secondary prevention of oesophageal varices. Survival may have increased in comparison with endoscopic therapy. Further research was required. These cautious conclusions and recommendations for research appear appropriate given the limitations of the evidence. Authors' objectives To determine the effects of isosorbidemononitrate alone or in combination with either beta-blockers or endoscopic therapy
Efficacy of beta-adrenergic blocker plus 5-isosorbidemononitrate and endoscopic band ligation for prophylaxis of esophageal variceal rebleeding: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Misoprosotol and IsosorbideMononitrate for Induction of Second Trimester Abortion Misoprosotol and IsosorbideMononitrate for Induction of Second Trimester Abortion - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Misoprosotol and IsosorbideMononitrate for Induction of Second Trimester Abortion The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03407521 Recruitment Status : Completed First Posted : January 23, 2018 Last Update Posted : February 28, 2018 Sponsor: Ain Shams University Information
Effectiveness of vinpocetine and isosorbide-5-mononitrate on experimental schistosomiasis mansoni: Biochemical and immunohistochemical study. Schistosomiasis is one of the most important tropical and subtropical devastating diseases, where praziquantel is the sole drug of choice. Praziquantel effectively kills the adult worms, however, drug resistance has been repeatedly reported. Moreover, there is currently no efficient anti-fibrotic therapy available for chronic schistosomiasis. So, novel (...) drugs which exert anti-fibrotic efficacy are urgently needed. This research is complementary to our previous work that evaluated the anti-schistosomal effects of the anti-inflammatory vinpocetine, as well as the vasodilator and the anti-oxidant isosorbide-5-mononitrate. In the present study, we assessed the therapeutic efficacies of drugs in Swiss albino female mice experimentally infected with an Egyptian strain of Schistosoma mansoni, using some biochemical and immunohistochemical parameters. Our
A comparative study on the anti-schistosomal and hepatoprotective effects of vinpocetine and isosorbide-5-mononitrate on Schistosoma mansoni-infected mice. Schistosomiasis is a remarkable public health problem in developing countries. Presently, praziquantel is the optional drug for all human schistosomiasis. Owing to the increased praziquantel resistance, there is an urgent need to develop new alternatives. This study aims at determining the anti-schistosomal and/or the hepatoprotective (...) effects of the anti-inflammatory drug; vinpocetine, and the vasodilator and the nitric oxide donor; isosorbide-5-mononitrate, in comparison to praziquantel. In the present research, the therapeutic efficacies of these drugs were assessed in Swiss albino female mice (CD-I strain) experimentally infected with an Egyptian strain of Schistosoma mansoni, using some general, parasitological, and histopathological parameters. In this work, praziquantel significantly reduced worm burden and hepatic egg load
Beta-blockers alone or in combination with isosorbidemononitrate for secondary prevention of bleeding from gastro-esophageal varices in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files
Poor tolerance and limited effects of isosorbide-5-mononitrate in microvascular angina. To assess the effects of isosorbide-5-mononitrate (ISMN) in patients with microvascular angina (MVA).We randomized 20 MVA patients, treated with a β-blocker or a calcium antagonist, to 60 mg slow-release ISMN (halved to 30 mg if not tolerated) or placebo once a day for 4 weeks; the patients were then switched to the other treatment for another 4 weeks. Their clinical status was assessed with the Seattle
Comparative efficacy and safety of dinoprostone, misoprostol and isosorbidemononitrate (IMN) for cervical ripening in outpatient settings: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites
Beta-blockers alone or with isosorbidemononitrate for primary prevention in adults with cirrhosis and gastro-oesophageal varices [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith
IsosorbideMononitrate in Heart Failure with Preserved Ejection Fraction. Nitrates are commonly prescribed to enhance activity tolerance in patients with heart failure and a preserved ejection fraction. We compared the effect of isosorbidemononitrate or placebo on daily activity in such patients.In this multicenter, double-blind, crossover study, 110 patients with heart failure and a preserved ejection fraction were randomly assigned to a 6-week dose-escalation regimen of isosorbide (...) pro-brain natriuretic peptide (NT-proBNP).In the group receiving the 120-mg dose of isosorbidemononitrate, as compared with the placebo group, there was a nonsignificant trend toward lower daily activity (-381 accelerometer units; 95% confidence interval [CI], -780 to 17; P=0.06) and a significant decrease in hours of activity per day (-0.30 hours; 95% CI, -0.55 to -0.05; P=0.02). During all dose regimens, activity in the isosorbidemononitrate group was lower than that in the placebo group (-439
Comparison of topical isosorbidemononitrate, topical diltiazem, and their combination in the treatment of chronic anal fissure. Chronic anal fissure is a painful condition that is associated with an increase in internal anal sphincter pressure. The main aim of this study is to evaluate the efficacy and adverse effects of topical isosorbide 5 mononitrate and topical diltiazem, when administered either as single agents or in combination, in the treatment of anal fissure.Patients with chronic (...) anal fissure were enrolled in the study. They were randomized into three groups: Group A (0.2% isosorbide 5 mononitrate users), Group B (2% diltiazem users), and Group C (2%diltiazem + 0.2% isosorbide 5 mononitrate users). Pain was evaluated using a visual analog scale (VAS). Level of strain during defecation was graded on a 4-point scale.A total of 55 patients were enrolled in the study. The average ages of patients in Groups A, B, and C were 37.94 ± 16.19, 42.83 ± 13.21, 40 ± 13.58 years
The impact of isosorbidemononitrate on cervical ripening and labor induction in primiparous women with term pregnancy: A double-blind, randomized, controlled trial. The most favorable method for cervical ripening is not fully agreed upon by practitioners; however, vaginal administration of isosorbidemononitrate (IMN) is considered a low-risk method of labor induction for pregnant women at full term. Our study was designed to assess the effect of IMN on cervical ripening and labor induction
Comparison of the effects of a controlled-release formulation of isosorbide-5-mononitrate and conventional isosorbide dinitrate on exercise performance in men with stable angina pectoris. Thirty-three men with stable exercise-induced angina pectoris entered a randomized, double-blind, crossover study in which controlled-release isosorbide-5-mononitrate 60 mg once daily was compared with conventional isosorbide dinitrate 20 mg 3 times daily. Each drug was given for 2 weeks. Twenty-eight patients (...) completed the study and data on exercise variables are available in 23 patients. Treatment with either drug resulted in significant antianginal effects, when measured 6 hours after a single dose and after 2 weeks of therapy compared with baseline placebo; however, there were significantly fewer signs of myocardial ischemia during treatment with isosorbide-5-mononitrate. There was no evidence of tolerance to either drug treatment but a significant attenuation of resting blood pressure
Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate. In a randomized, double-blind, placebo controlled, crossover study, the antianginal and anti-ischemic effects of a controlled release formulation of isosorbide-5-mononitrate 60 mg once daily and of a standard formulation of isosorbide dinitrate 30 mg qid, were assessed during the first day of treatment and after seven days of sustained therapy. In comparison to placebo (...) , the acute administration of isosorbide-5-mononitrate increased treadmill walking time at 4 and 8 h, and isosorbide dinitrate prolonged treadmill walking time when tested at 4 h after each of the first three doses. During sustained therapy, isosorbide dinitrate produced no significant changes over placebo values. Isosorbide-5-mononitrate prolonged treadmill walking time 4, 8 and 12 h after morning dosing by 54, 41 and 52 s, but these changes were not significant compared to placebo. Treadmill walking
Endoscopic ligation compared with combined treatment with nadolol and isosorbidemononitrate to prevent recurrent variceal bleeding. After an episode of acute bleeding from esophageal varices, patients are at high risk for recurrent bleeding and death. We compared two treatments to prevent recurrent bleeding--endoscopic ligation and combined medical therapy with nadolol and isosorbide mononitrate.We randomly assigned 144 patients with cirrhosis who were hospitalized with esophageal variceal (...) bleeding to receive treatment with endoscopic ligation (72 patients) or the combined medical therapy (72 patients). Sessions of ligation were repeated every two to three weeks until the varices were eradicated. The initial dose of nadolol was 80 mg orally once daily, with adjustment according to the resting heart rate; isosorbidemononitrate was given in increasing doses, beginning at 20 mg once a day at bed time and rising over the course of one week to 40 mg orally twice a day, unless side effects
Randomised placebo-controlled trial of outpatient (at home) cervical ripening with isosorbidemononitrate (IMN) prior to induction of labour--clinical trial with analyses of efficacy and acceptability. The IMOP study. To determine whether isosorbidemononitrate (IMN), self-administered vaginally by women at home, improves the process of induction of labour.Randomised double blind placebo-controlled trial.Large UK maternity hospital.Nulliparous women with a singleton pregnancy, cephalic
Comparison of isosorbidemononitrate and misoprostol for cervical ripening in termination of pregnancy between 8 and 12 weeks: a randomized controlled trial. The present study was undertaken to compare the efficacy of isosorbidemononitrate (IMN) and misoprostol for cervical ripening in termination of pregnancy between 8 and 12 weeks.This prospective randomized single blind study enrolled 40 women with singleton pregnancy seeking surgical termination of pregnancy between 8 and 12 weeks
Comparative evaluation of isosorbidemononitrate and alendronate in management of postmenopausal osteoporosis. Osteoporosis, a skeletal disorder that adversely affects bone strength , is common among postmenopausal women primarily due to reduced ovarian estrogens.The present study was taken up to evaluate the role of isosorbidemononitrate (IMN) in the management of postmenopausal osteoporosis and to compare its efficacy with that of alendronate.This prospective systematic randomized study